Table 8.

SCORPIO safety results.

	Mirabegron 50 mg	Mirabegron 100 mg	Placebo	Tolterodine
Dry mouth	2.8%	2.8%	2.6%	10.1%
Hypertension	5.9%	5.4%	7.7%	8.1%
Pulse rate increases versus placebo	Am +0.8 Pm +0.7 Both groups similar to tolterodine versus placebo	Am +1.6 Pm +2.0
Number of patients with notable shift in PVR >300 ml	1	2		1
Discontinuing due to TEAE	4.9%	3.2%	2.6%	4.4%

PVR, post-void residual volume; TEAE, treatment-emergent adverse event.